Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Nootropics / Neuroprotective

65 In the index

Ladostigil LADO

An experimental drug studied in human trials for mild memory problems in aging, working on two different brain pathways at once. Results have been mixed, without clear proof it slows the progression to full dementia, and it remains unapproved.

Also known as TV-3326

Effects Focus Mood
Routes Oral
Legal status Research chemical
WADA Not listed

3D Molecular Structure of C16H20N2O2

Drag to rotate · scroll to zoom

  • Carbon
  • Hydrogen
  • Nitrogen
  • Oxygen

Chemistry

Formula
C16H20N2O2
Molar mass
272.34
CAS
209394-27-4
PubChem CID
208907

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; investigational
Reported range Phase II trial doses: 10 mg/day
Route Oral
Frequency Once daily
Duration Trial durations of up to a year

An investigational dual cholinesterase/MAO-B inhibitor studied for mild cognitive impairment; not an approved product.

Where this comes from Published Phase II clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.